Tag Archives: lenzilumab

Humanigen Cancels Collaboration with Gilead (Kite) to Test Lenzilumab with Other Commercial CD19 CAR-Ts; FDA Accepts Allogene’s TurboCAR ALLO-605 (BCMA CAR-T) IND; First Patient Dosed with Ziopharm’s RPM CD19 CAR-T in Taiwan; No Regulatory Updates for Cilta-cel in JNJ’s Q1 2021 Earnings Call

A series of cell therapy-related news items have been observed:

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.